Dimethoxybenzohomoadamantane-based soluble epoxide hydrolase inhibitors: in vivo efficacy in a murine model of chemotherapy-induced neuropathic pain [Dataset]

The soluble epoxide hydrolase (sEH) has recently emerged as a promising target for the treatment of several pain-related conditions. Herein, we report the design and synthesis of a peripherally restricted sEH inhibitor with high potency and good Drug Metabolism and Pharmacokinetics (DMPK) properties...

Descripción completa

Detalles Bibliográficos
Autores: Codony, Sandra, Jora, Beatrice, Santos-Caballero, Miriam, Qiu, Qiongju, Calvó-Tusell, Carla, Escriche, Celia, Turcu, Andreea L., Prischi, Filippo, Bartra, Clara, Val, Cristina, Morisseau, Christophe, Pérez, Belén, Bertran-Mostazo, Andrea, Osuna, Sílvia, Corpas, Rubén, Griñán-Ferré, Christian, Galdeano, Carles, Loza, M Isabel, Pallàs, Mercè, Sanfeliu, Coral, Hammock, Bruce D., Brea, José, Feixas, Ferran, Conte, Maria R., Cobos, Enrique J., Vázquez, Santiago
Tipo de recurso: conjunto de datos
Fecha de publicación:2025
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:dnet:digitalcsic_::756eff34b5884d1c29ad84dd2da787c5
Acceso en línea:http://hdl.handle.net/10261/419746
https://digital.csic.es/handle/10261/419739
Access Level:acceso abierto
Palabra clave:Benzohomoadamantane
Chemotherapy-induced neuropathic pain
Epoxyeicosatrienoic acids
Soluble epoxide hydrolase
Urea
Descripción
Sumario:The soluble epoxide hydrolase (sEH) has recently emerged as a promising target for the treatment of several pain-related conditions. Herein, we report the design and synthesis of a peripherally restricted sEH inhibitor with high potency and good Drug Metabolism and Pharmacokinetics (DMPK) properties. Molecular dynamics and X-ray crystallography helped reveal the binding of these inhibitors to sEH. The selected compound showed a robust analgesic effect in a dose-dependent manner in a murine model of chemotherapy-induced neuropathic pain (CINP). Moreover, the compound also prevented the development of paclitaxel-induced neuropathic pain. Overall, these results suggest that peripheral inhibition of sEH might constitute a novel therapy to prevent and treat CINP.